40 research outputs found
Portuguese recommendations for the use of biological therapies in patients with psoriatic arthritis - 2015 update
OBJECTIVE: To update recommendationsforthe treatment
of psoriatic arthritis with biological therapies, endorsed
by the Portuguese Society of Rheumatology (SPR).
METHODS: These treatment recommendations were formulated
by Portuguese rheumatologists based on literature
evidence and consensus opinion. At a national
meeting the 16 recommendations included in this
document were discussed and updated. The level of
agreement among Portuguese Rheumatologists was assessed
using an online survey. A draft of the full text of
the recommendations was then circulated and suggestions
were incorporated. A final version was again circulated
before publication.
RESULTS: A consensus was achieved regarding the initiation,
assessment of response and switching biological
therapies in patients with psoriatic arthritis (PsA).
Specific recommendations were developed for several
disease domains: peripheral arthritis, axial disease, enthesitis
and dactylitis.
CONCLUSION: These recommendations may be used for
guidance in deciding which patients with PsA should be
treated with biological therapies. They cover a rapidly
evolving area oftherapeutic intervention.Asmore evidence
becomes available and more biological therapies are licensed,
these recommendations will have to be updated
The Portuguese Society of Rheumatology position paper on the use of biosimilars
Biotechnological drugs have become a fundamental resource for the treatment of rheumatic patients. Patent expiry of some of these drugs created the opportunity for biopharmaceutical manufacturers to develop biosimilar drugs intended to be as efficacious as the originator product but with a lower cost to healthcare systems. Due to the complex manufacturing process and highly intricate structure of biologicals, a biosimilar can never be an exact copy of its reference product. Consequently, regulatory authorities issued strict preclinical and clinical guidelines to ensure safety and efficacy equivalence and, in September 2013, the biosimilar of infliximab was the first biosimilar monoclonal antibody to be authorized for use in the European Union. The current document is a position statement of the "Sociedade Portuguesa de Reumatologia" (Portuguese Society of Rheumatology) on the use of biosimilar drugs in rheumatic diseases. Two systematic literature reviews were performed, one concerning clinical trials and the other one concerning international position papers on biosimilars. The results were presented and discussed in a national meeting and a final position document was discussed, written and approved by Portuguese rheumatologists. Briefly, this position statement is contrary to automatic substitution of the originator by the biosimilar, defends either a different INN or the prescription by brand name, supports that switching between biosimilars and the originator molecule should be done after at least 6 months of treatment and based on the attending physician decision and after adequate patient information, recommends the registration of all biosimilar treated patients in Reuma.pt for efficacy, safety and immunogenicity surveillance, following the strategy already ongoing for originators, and opposes to extrapolation of indications approved to the originator to completely different diseases and/or age groups without adequate pre-clinical, safety or efficacy data.info:eu-repo/semantics/publishedVersio
Osteoarthritis medical labelling and health-related quality of life in the general population
Structural characterization of the bglH gene encoding a beta-glucosidase-like enzyme in an endophytic Bacillus pumilus strain
CONCOMITANT FACTORS AFFECTING GESTATION LENGTH AND PERINATAL MORTALITY IN HOLSTEIN-FRIESIAN COWS
The objective of this study was to identify and quantify factors presenting simultaneous moderate or strong influence on gestation length and perinatal mortality (until 4 days postpartum) in Holstein-Frisian dams. The overall gestation length least square mean was 278.2 ± 0.2 days (n = 962). According to the multivariate model (p < 0.001), a shorter gestation length was observed in Holstein-Friesian (–2.0 days) and Red Holstein-Friesian (–3.9 days) breed sires whereas Brown Swiss (2.0 days) and Aberdeen-Angus (2.3 days) breed sires showed a longer gestation length. Primiparous cows and twin pregnancies, as well calving in June and July, shortened gestation length in –1.4, –4.0, –1.9 and –1.8 days, respectively. The perinatal mortality incidence was 7.4% (n = 72) and was more likely to occur in twin pregnancies (p < 0.01) than in pregnancies carrying female (odds ratio = 8.1) or male (odds ratio = 7.9) singletons, as well in primiparous (odds ratio = 2.6) than multiparous dams (p < 0.05). In conclusion, parity and twinning were the major factors which influenced simultaneously gestation length of dams and perinatal mortality incidence. Nevertheless, all studied factors had a significant impact on gestation length and should be considered for reproductive management programs of dairy herds
Near-Infrared Radiation-Based Mild Photohyperthermia Therapy of Non-Melanoma Skin Cancer with PEGylated Reduced Nanographene Oxide
Using a one-step thermal reduction and non-covalent chemical functionalization process, PEGylated reduced nanographene oxide (rGOn-PEG) was produced from nanographene oxide (GOn) and characterized in terms of particle size, dispersion stability, chemistry, and photothermal properties, in view of its use for photothermal therapy (PTT) of non-melanoma skin cancer. GOn infrared spectrum presented more intense bands assigned to oxygen containing functional groups than observed for rGOn-PEG. GOn C/O ratio decreased more than 50% comparing with rGOn-PEG and nitrogen was present in the latter (N at % = 20.6) due to introduction of PEG-NH2. Thermogravimetric analysis allowed estimating the amount of PEG in rGOn-PEG to be of about 56.1%. Simultaneous reduction and PEGylation increased the lateral dimensions from 287 ± 139 nm to 521 ± 397 nm, as observed by transmission electron microscopy and dynamic light scattering. rGOn-PEG exhibited ≈13-fold higher absorbance in the near-infrared radiation (NIR) region, as compared to unmodified GOn. Low power (150 mW cm−2) NIR irradiation using LEDs resulted in rGOn-PEG heating up to 47 °C, which is within the mild PTT temperature range. PEGylation strongly enhanced the dispersibility of rGOn in physiological media (phosphate buffered saline, fetal bovine serum, and cell culture medium) and also improved the biocompatibility of rGOn-PEG, in comparison to GOn (25–250 μg mL−1). After a single NIR LED irradiation treatment of 30 min, a decrease of ≈38% in A-431 cells viability was observed for rGOn-PEG (250 μg mL−1). Together, our results demonstrate the potential of irradiating rGOn-PEG using lower energy, cheaper, smaller, and safer LEDs, as alternative to high power lasers, for NIR mild hyperthermia therapy of cancer, namely non-melanoma skin cancer